George Massaro sold $20k of CRL
director at CHARLES RIVER LABORATORIES INTERNATIONAL, INC.. 140 shares at an average of $140.74, traded May 14, 2025, filed May 15, 2025.
Score components
- +15RoleDirector
- 0Trade size$20k at market
- 0Share of holdings soldSold 2.4% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001127602-25-014486, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 14, 2025 | SOpen-market sale Common Stock10b5-1 | -91 | $139.95 | $13k | 5,764 | May 15, 2025 |
| May 14, 2025 | SOpen-market sale Common Stock10b5-1 | -21 | $140.78 | $2,956 | 5,743 | May 15, 2025 |
| May 14, 2025 | SOpen-market sale Common Stock10b5-1 | -14 | $141.85 | $1,986 | 5,729 | May 15, 2025 |
| May 14, 2025 | SOpen-market sale Common Stock10b5-1 | -7 | $143.77 | $1,006 | 5,722 | May 15, 2025 |
| May 14, 2025 | SOpen-market sale Common Stock10b5-1 | -7 | $145.54 | $1,019 | 5,715 | May 15, 2025 |
Related signals
Other insiders at CHARLES RIVER LABORATORIES INTERNATIONAL, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Shannon M Parisotto CEVP, Disc & Safety Assessment | $303k 981 shares | -17% | |
| 17Weak | CRLbuy CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Glenn Coleman EVP & Chief Financial Officer | $2,974 10 shares | +0% | |
| 26Weak | CRLsell CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Joseph W LaPlume EVP, Corp Strategy & Develop | $126k 800 shares | -3% | |
| 22Weak | CRLsell CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Joseph W LaPlume EVP, Corp Strategy & Develop | $60k 400 shares | -2% | |
| 3Weak | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | George Massaro director | $19k 140 shares | -2% | |
| 31Weak | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Joseph W LaPlume EVP, Corp Strategy & Develop | $73k 500 shares | -2% | |
| 41Moderate | CRLsell CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Joseph W LaPlume EVP, Corp Strategy & Develop | $715k 4,400 shares | -18% | |
| 41Moderate | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Birgit Girshick Corporate Executive VP & COO | $249k 1,514 shares | +3% | |
| 58Moderate | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | James C Foster Chairman, President and CEO | $1.0M 6,075 shares | +3% | |
| 50Moderate | CRLsell CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Richard F Wallman director | $1.6M 7,621 shares | -40% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.